ReviewActa pharmaceutica Sinica. B2021
Membrane-disruptive peptides/peptidomimetics-based therapeutics: Promising systems to combat bacteria and cancer in the drug-resistant era.
Review in Acta pharmaceutica Sinica. B, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 71 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
71 citing papers in PubMed, 167 citations in OpenAlex.
- Recent Progress in Antimicrobial Peptides (AMPs) Towards Enhanced Selectivity and Reduced Cytotoxicity by Molecular Engineering.Biotechnology and bioengineering · 2026Review
- Article
- Discovery of novel tumor-targeting peptide-oncolytic peptide based conjugates (PPCs): A new paradigm for targeted oncolytic-immunotherapy.Acta pharmaceutica Sinica. B · 2026Article
- Anticancer Activity of the Antimicrobial Myristoylated Peptide Myr-B in HeLa Cells: Cytotoxic, Membrane-Disruptive and Proteomic Insights.International journal of molecular sciences · 2026Article
- Structural Modification and Conjugation Strategies of Antimicrobial Peptides for Topical Anti-Infective Applications.Antibiotics (Basel, Switzerland) · 2026Review
- Cell-Free DNA-Based Theranostics for Inflammatory Disorders.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Review
- Skin-penetrating peptides derived from computational simulation improve transdermal absorption and facilitate topical treatment of melanoma.Acta pharmaceutica Sinica. B · 2026Article
- The Dual Role of Natural Peptides in Cancer Therapy: Anticancer and Immunomodulatory Perspectives.Oncology research · 2026Review
- Menthol's disruptive effects on kanamycin-resistant Escherichia coli energy metabolism and ion fluxes.Biophysical reports · 2025Article
- A biodegradable antimicrobial oligomer-containing hydrogel for drug-resistant bacteria-infected skin wound treatment.Pharmaceutical science advances · 2025Article
- A Self-Assembling Peptide with Nanoparticle-to-Fibril Transformation Exhibits Multimodal Antimicrobial Activity through Membrane Disruption and Quorum-Sensing Inhibition.Small (Weinheim an der Bergstrasse, Germany) · 2025Article
- Small Interfering RNA Carriers for Oncotherapy: A Preclinical Overview.Pharmaceutics · 2025Review
- Wound Healing: Molecular Mechanisms, Antimicrobial Peptides, and Emerging Technologies in Regenerative Medicine.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Design, Structural Stability, Membrane Binding, and Antibacterial Activity of Novel Antimicrobial Peptides Derived from Wuchuanin-A1.Life (Basel, Switzerland) · 2025Article
- Article
- Identification and Validation of Promising Targets and Inhibitors of Biofilm Formation inPathogens (Basel, Switzerland) · 2025Article
- Article
- New Generation Antibiotics Derived from DABCO-Based Cationic Polymers.Antibiotics (Basel, Switzerland) · 2025Article
- Potential application of Healitide-GP1, a novel antibacterial peptide, in wound healing: in vitro studies.Scientific reports · 2025Article
- Nanoparticles-incorporated hydrogel microneedle for biomedical applications: Fabrication strategies, emerging trends and future prospects.Asian journal of pharmaceutical sciences · 2025Review
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Membrane-disruptive peptides/peptidomimetics (MDPs) are antimicrobials or anticarcinogens that present a general killing mechanism through the physical disruption of cell membranes, in contrast to conventional chemotherapeutic drugs, which act on precise targets such as DNA or specific enzymes. Owing to their rapid action, broad-spectrum activity, and mechanisms of action that potentially hinder the development of resistance, MDPs have been increasingly considered as future therapeutics in the drug-resistant era. Recently, growing experimental evidence has demonstrated that MDPs can also be utilized as adjuvants to enhance the therapeutic effects of other agents. In this review, we evaluate the literature around the broad-spectrum antimicrobial properties and anticancer activity of MDPs, and summarize the current development and mechanisms of MDPs alone or in combination with other agents. Notably, this review highlights recent advances in the design of various MDP-based drug delivery systems that can improve the therapeutic effect of MDPs, minimize side effects, and promote the co-delivery of multiple chemotherapeutics, for more efficient antimicrobial and anticancer therapy.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.